Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Dec 8;324(22):2324-2327.
doi: 10.1001/jama.2020.19395.

Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants

Giancarlo Natalucci  1 , Bea Latal  2 , Brigitte Koller  1 , Christoph Rüegger  1 , Beate Sick  3 , Leonhard Held  3 , Jean-Claude Fauchère  1 ; Swiss EPO Neuroprotection Trial Group
Affiliations
Clinical Trial

Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants

Giancarlo Natalucci et al. JAMA. .

Abstract

This study reports 5-year neurodevelopmental outcomes for Swiss children born before 32 weeks’ gestation and randomized at birth to receive early high-dose recombinant human erythropoietin (rhEpo) vs placebo.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Comment in

References

    1. Fischer HS, Reibel NJ, Bührer C, Dame C. Prophylactic early erythropoietin for neuroprotection in preterm infants: a meta-analysis. Pediatrics. 2017;139(5):e20164317. doi: 10.1542/peds.2016-4317 - DOI - PubMed
    1. Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. Cochrane Database Syst Rev. 2020;2:CD004863. doi: 10.1002/14651858.CD004863.pub6 - DOI - PMC - PubMed
    1. Natalucci G, Latal B, Koller B, et al. ; Swiss EPO Neuroprotection Trial Group . Effect of early prophylactic high-dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA. 2016;315(19):2079-2085. doi: 10.1001/jama.2016.5504 - DOI - PubMed
    1. Fauchère JC, Koller BM, Tschopp A, et al. Safety of early high-dose recombinant erythropoietin for neuroprotection in very preterm infants. J Pediatr. 2015;167(1):52-57. doi: 10.1016/j.jpeds.2015.02.052 - DOI - PubMed
    1. Juul SE, Comstock BA, Wadhawan R, et al. ; PENUT Trial Consortium . A randomized trial of erythropoietin for neuroprotection in preterm infants. N Engl J Med. 2020;382(3):233-243. doi: 10.1056/NEJMoa1907423 - DOI - PMC - PubMed

Publication types

MeSH terms